UroGen CMO sells 60,677 shares at $47 average price

UroGen Pharma Ltd. (URGN) reported that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares on 2026-08-20 in an open market or private transaction.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) reported that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares on 2026-08-20 in an open market or private transaction. The weighted average sale price was $47.05 per share, with prices ranging from $46.30 to $49.70. Following the sale, Schoenberg directly holds 59,086 ordinary shares.

Insider Trade Summary

Net Seller: 60,677 shares

Net Sell 1 txn

Insider Schoenberg Mark

Role Chief Medical Officer

Sold 60,677 shs ($2.85M)

Type	Security	Shares	Price	Value
Sale	ordinary shares F1	60,677	$47.05	$2.85M

Holdings After Transaction: ordinary shares — 59,086 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 60,677 ordinary shares Weighted average sale price: $47.05 per share Sale price range: $46.30 to $49.70 per share +1 more

4 metrics

Shares sold 60,677 ordinary shares Sale transaction on 2026-08-20 reported by Chief Medical Officer Mark Schoenberg

Weighted average sale price $47.05 per share Average price for 60,677 ordinary shares sold on 2026-08-20

Sale price range $46.30 to $49.70 per share Range of prices for multiple transactions included in the reported sale

Shares owned after transaction 59,086 ordinary shares Direct holdings of Mark Schoenberg following the 2026-08-20 sale

Key Terms

weighted average price, ordinary shares, open market or private transaction

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

ordinary shares financial

"security_title: ordinary shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did URGN report for Mark Schoenberg on this Form 4?

The filing reports that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares of UroGen Pharma Ltd. on 2026-08-20 in a sale classified as an open market or private transaction.

At what price were the URGN shares sold in Mark Schoenberg’s transaction?

The reported price is a weighted average of $47.05 per share. According to the footnote, the 60,677 shares were sold in multiple trades at prices ranging from $46.30 to $49.70 per share, inclusive.

How many URGN shares does Mark Schoenberg hold after this reported sale?

After the reported sale, Mark Schoenberg directly holds 59,086 ordinary shares of UroGen Pharma Ltd., as stated in the Form 4’s post-transaction ownership column.

Was Mark Schoenberg’s URGN share sale made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not checked, so the reported transaction is not affirmed as having been made under a Rule 10b5-1 trading plan in this filing.

What additional pricing detail does the footnote provide for the URGN insider sale?

The footnote explains that the $47.05 price is a weighted average, with the 60,677 shares sold in multiple transactions at prices between $46.30 and $49.70. Full per-trade price details are available on request from the issuer or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:03 PM EDT Accepted by SEC EDGAR 08/24/2026 - 05:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoenberg Mark

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ordinary shares	08/20/2026		S		60,677	D	$47.05(1)	59,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Jason D. Smith, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)